Enveric Biosciences (ENVB) Consolidated Net Income (2010 - 2026)
Enveric Biosciences (ENVB) posted Consolidated Net Income of -$1.6 million for Q1 2026, down 84.34% sequentially from -$886115.0 in Q4 2025, and up 25.24% YoY from -$1.3 million in Q1 2025.
Enveric Biosciences (ENVB) Consolidated Net Income (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Consolidated Net Income for 17 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly Consolidated Net Income rose 25.24% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.9 million (up 25.7% YoY) and the FY2025 annual result came in at -$5.6 million, up 41.29% from the prior year.
- Consolidated Net Income retreated to -$1.6 million in Q1 2026 per ENVB's latest filing, from -$886115.0 in the prior quarter.
- Over five years, Consolidated Net Income peaked at $3.6 million in Q4 2023 and troughed at -$6.4 million in Q2 2023.
- A 5-year average of -$2.6 million and a median of -$2.5 million in 2022 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2023 and 2024: Consolidated Net Income soared 224.34% in 2023, then plunged 187.1% in 2024.
- Over 5 years, Consolidated Net Income stood at -$2.9 million in 2022, then jumped by 224.34% to $3.6 million in 2023, then slumped by 187.1% to -$3.2 million in 2024, then surged by 71.91% to -$886115.0 in 2025, then slumped by 84.34% to -$1.6 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$1.6 million, -$886115.0, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | -3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.63 Mn |
| Dec 31, 2025 | -886,115.00 |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -2.18 Mn |
| Dec 31, 2024 | -3.15 Mn |
| Sep 30, 2024 | -2.08 Mn |
| Jun 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -2.46 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | -2.82 Mn |
| Jun 30, 2023 | -6.36 Mn |
| Mar 31, 2023 | -4.68 Mn |
| Dec 31, 2022 | -2.91 Mn |
| Sep 30, 2022 | -2.48 Mn |
| Jun 30, 2022 | -4.71 Mn |
| Mar 31, 2022 | -4.80 Mn |
| Dec 31, 2021 | -50.98 Mn |
| Sep 30, 2021 | -4.25 Mn |
| Jun 30, 2021 | -3.45 Mn |